Company news
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news
Sangamo Therapeutics, Inc. news releases on 6ix. Latest, Feb 17, 2021: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call…
Press releases — page 3
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
February 16, 2021
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
January 31, 2021
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
January 5, 2021
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
December 6, 2020
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
November 3, 2020
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
October 27, 2020
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
October 6, 2020
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
September 10, 2020
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
August 9, 2020
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
August 4, 2020
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
July 29, 2020
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
July 28, 2020
Sangamo Announces R&D Organization Changes
June 23, 2020
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
May 28, 2020
Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
May 11, 2020
Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
May 10, 2020
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
May 6, 2020
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
May 3, 2020
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
April 27, 2020
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
April 20, 2020
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
April 16, 2020
Sangamo Announces Closing of Biogen Collaboration Agreement
April 8, 2020
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
February 26, 2020
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
February 24, 2020
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
February 11, 2020
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 8, 2020
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
December 22, 2019
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
December 16, 2019
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
December 5, 2019
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
November 25, 2019
Sangamo Therapeutics Announces New Scientific Advisory Board
November 7, 2019
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
November 5, 2019
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
October 31, 2019
Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast
October 29, 2019
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
September 29, 2019
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
July 30, 2019
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
July 30, 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
June 20, 2019
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
May 9, 2019
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
April 30, 2019
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
April 14, 2019
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
April 7, 2019
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
April 3, 2019
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
April 2, 2019
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
April 1, 2019
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
April 1, 2019
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
March 31, 2019